Can droxidopa be used to treat postural orthostatic tachycardia syndrome (POTS) in adults?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Droxidopa for POTS

Droxidopa is NOT recommended for the treatment of POTS, as it is FDA-approved only for neurogenic orthostatic hypotension (nOH), not POTS, and current guidelines do not include it among recommended pharmacological therapies for POTS.

Why Droxidopa Is Not Appropriate for POTS

The 2020 Canadian Cardiovascular Society guidelines explicitly list the most common medications used in POTS management as: midodrine, propranolol, pyridostigmine, fludrocortisone, ivabradine, clonidine, and intermittent IV normal saline 1. Droxidopa is notably absent from this list.

The FDA label for droxidopa clearly states it is indicated for "symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure" 2. POTS is fundamentally different from nOH—POTS is defined by excessive orthostatic tachycardia WITHOUT orthostatic hypotension 1. This is a critical distinction that makes droxidopa mechanistically inappropriate.

Limited and Disappointing Evidence in POTS

The available research on droxidopa in POTS is sparse and discouraging:

  • A 2017 retrospective study of 37 POTS patients found that while some symptoms improved (dizziness decreased from 91.9% to 75.7%), only 27% reported improved quality of life, and 40.5% stopped treatment due to side effects or ineffectiveness 3. There was no significant change in blood pressure.

  • A 2023 systematic review acknowledged droxidopa has been studied but noted most POTS drug studies are severely underpowered with sample sizes of only 10-50 subjects 4.

Recommended Treatment Algorithm for POTS

First-Line: Non-Pharmacological (ALL patients)

  • Fluid intake: ≥3 L daily 1
  • Salt intake: 10 g NaCl daily 1
  • Exercise training: Semi-recumbent aerobic exercise (rowing, recumbent cycling, swimming) at least 4 days/week for ≥30 minutes 1
  • Compression garments: Waist-high stockings (20-30 mm Hg) 1
  • Head-up tilt sleeping: >10° elevation 1

Second-Line: Pharmacological (if disabling symptoms persist)

For patients with low blood pressure phenotype:

  • Midodrine 2.5-15 mg every 4 hours up to 3 times daily (Strong Recommendation, Moderate-Quality Evidence) 1

For patients with high heart rate and palpitations:

  • Low-dose propranolol 10-20 mg four times daily (Strong Recommendation, Moderate-Quality Evidence) 1
  • Avoid long-acting formulations—they worsen fatigue and exercise tolerance 1

Additional options:

  • Pyridostigmine: Especially useful when combined with β-blockers; helpful in patients with constipation but avoid in those with diarrhea or bladder dysfunction 1
  • Ivabradine 2.5-7.5 mg twice daily: For heart rate control (Weak Recommendation, Low-Quality Evidence) 1
  • Fludrocortisone: For volume expansion when oral salt intake inadequate; avoid in migraine patients; monitor potassium 1

Critical Pitfalls to Avoid

  1. Do not confuse POTS with nOH: POTS patients do NOT have orthostatic hypotension by definition. Using droxidopa, which is designed to raise blood pressure in nOH, is mechanistically inappropriate 1, 2.

  2. Supine hypertension risk: Droxidopa carries a black box warning for supine hypertension 2. POTS patients, particularly those with hyperadrenergic phenotype, may already have elevated blood pressure and would be at increased risk.

  3. No long-term evidence: The FDA label notes droxidopa's effectiveness beyond 2 weeks has not been established 2, making it unsuitable for chronic POTS management.

  4. Cost and access barriers: The 2017 study noted many patients couldn't obtain droxidopa due to insurance and cost concerns 3.

Bottom Line

Use guideline-recommended therapies: Start with midodrine for hypotensive patients or low-dose propranolol for tachycardic patients, both of which have moderate-quality evidence supporting their use in POTS 1. Droxidopa should be reserved for its FDA-approved indication of neurogenic orthostatic hypotension, not POTS.

Related Questions

In a hypovolemic patient with postural orthostatic tachycardia syndrome (POTS), does increased dehydration cause greater heart‑rate increase and variability on standing and worsen gastrointestinal symptoms such as nausea?
I have hyperadrenergic postural orthostatic tachycardia syndrome (POTS) with controlled heart rate, but I still experience post‑prandial discomfort, tension, and feeling on edge after meals; how can I alleviate these symptoms?
How should beta‑blockers be used to treat postural orthostatic tachycardia syndrome (POTS)?
What non‑pharmacologic and pharmacologic strategies can I use to treat persistent morning sympathetic activation, palm and foot sweating, and discomfort on waking in a patient with hyperadrenergic postural orthostatic tachycardia syndrome (POTS) who previously experienced orthostatic and post‑prandial tachycardia?
What diet should a patient follow while taking midodrine for postural orthostatic tachycardia syndrome (POTS)?
What could cause lower abdominal pain, cardiac palpitations, and rib pain, and does this require urgent evaluation?
What is the percentage of tricyclic antidepressant (TCA) for a TA cross?
How long should a patient with hypertension and hypercholesterolemia continue atorvastatin therapy?
What is the recommended dosing schedule for droxidopa, including starting dose, titration increments, target range, maximum dose, and adjustments for renal impairment?
A 27-year-old woman presents with a 0.2 cm tender mass located between the helical crus and the cymba concha of the right ear for one week; what is the most likely diagnosis and appropriate treatment?
What is the appropriate management for a patient with lung contusion?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.